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Abstract 
Background and aims Clinical experience and observational studies suggest that individuals 
with coeliac disease are at increased risk of coronary heart disease (CHD), but the precise 
mechanism for this is unclear. Laboratory studies suggest that it may relate to tissue 
transglutaminase antibodies (tTGAs). Our aim was to examine whether seropositivity for 
tTGA and endomysial antibodies (EMAs) are associated with incident CHD in humans. 
Methods We used data from Mini-Finland Health Survey, a prospective cohort study of 
Finnish men and women aged 35-80 at study baseline 1978-80. TTGA and EMA 
seropositivities were ascertained from baseline blood samples and incident CHD events were 
identified from national hospitalisation and death registers. Poisson regression was used to 
examine the associations between antibody seropositivity and incident CHD. 
Results Of 6,887 men and women 562 were seropositive for tTGAs and 72 for EMAs. 
During a median follow-up of 26 years 2,367 individuals experienced a CHD event. We 
found no clear evidence for an association between tTGA positivity (hazard ratio, HR: 1.04, 
95% confidence interval, CI: 0.83, 1.30) or EMA positivity (HR: 1.16, 95% CI: 0.77, 1.74) 
and incident CHD, once pre-existing CVD and known CHD risk factors had been adjusted 
for. 
Conclusion We found no clear evidence for an association of tTGA or EMA seropositivity 
with incident CHD outcomes, suggesting that tTG autoimmunity is unlikely to be the 
biological link between coeliac disease and CHD. 
 
Keywords: coronary heart disease, CHD, tissue transglutaminase antibody, tTGA, 
endomysial antibody, EMA, cohort study  
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Introduction 
Coeliac disease is an autoimmune-mediated condition triggered by the ingestion of gluten, a 
storage protein in wheat, rye and barley[1]  Prolamine peptides from these cereals are 
deamidated by tissue transglutaminase (tTG) in the small intestine and in genetically 
susceptible individuals the deamidated peptides activate a T-cell driven immune response and 
production of immunoglobulin A class autoantibodies against tTG [2]. When this 
autoimmune reaction become chronic, it leads to small intestinal mucosal villous atrophy and 
crypt hyperplasia, which are currently the diagnostic gold standard for coeliac disease [3]. 
 
Coeliac disease can be effectively managed by excluding gluten from the patients’ diet, thus 
stopping the autoimmune response and reversing the mucosal damage [4].  Individuals with 
coeliac disease who consume gluten, either because they have not been diagnosed or because 
their adherence to a gluten-free diet is poor, have gluten-induced elevated circulating 
concentrations of tissue transglutaminase antibodies (tTGAs) and endomysial antibodies 
(EMAs) [5, 6]. These autoantibodies have been used as serological markers for unrecognised 
coeliac disease in general population-based screening studies, the findings of which suggest 
that clinically unrecognised coeliac disease is more common than was previously thought [7-
10]: it has been estimated that in addition to the 0.1-0.6% of the population with diagnosed 
coeliac disease, unrecognised coeliac disease may be present in up to 2% of the population in 
high income countries [11-13] .  
 
Clinically diagnosed coeliac disease co-occurs with various comorbidities, including 
neurological and liver abnormalities [14], certain cancers [15] and bone fractures [16],  and 
appears to be associated with an increased risk of cardiovascular outcomes, including 
coronary heart disease (CHD) [17]. However, the exact mechanism for these associations is 
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unclear. Laboratory studies have pointed to tissue transglutaminase autoimmunity as one 
potential link between coeliac and cardiovascular diseases. Findings from in-vivo and in-vitro 
studies suggest that tTG has the ability to enhance angiogenesis and that, by contrast, tTGAs 
can inhibit blood vessel formation. [18-20]. It is not known, however, whether these findings 
translate into humans. To explore this, we have examined the associations of tTGA and EMA 
seropositivity with incident coronary heart disease (CHD) using data from Mini-Finland 
Health Survey, a prospective population-based cohort study of over 6,000 Finnish men and 
women. 
 
Materials and methods 
Participants 
Details of  the design and data collection in Mini-Finland Health Survey have been reported 
previously and are provided in the Online Supplement [21]. Briefly, 7,217 men and women 
(90% of those recruited) aged 35-80 attended a baseline examination in 1978-80. The 
analyses presented here are based on 6,887 participants with complete data on serology, CHD 
outcomes and covariates (Online Supplement, Figure S1. Participant flow chart). 
 
Exposures and outcomes 
Seropositivity for tTGAs and EMAs were determined from baseline serum samples. Details 
of the assays have been reported previously and are provided in the Online Supplement [22]. 
All serum samples were tested for tTGA (Eu-tTG umana IGA, Eurospital S.p.A., Trieste, 
Italy; abbreviated as Eu-tTG). Positive samples were re-tested using another tTGA test 
(Celikey Tissue Transglutaminase IgA Antibody Assay, Phadia, Freiburg, Germany; 
abbreviated as Celikey-tTG) and an EMA test (indirect immunofluorescence, in-house test, 
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Coeliac Disease Study Group, Tampere University and Tampere University Hospital; 
abbreviated as EMA).   
 
Incident CHD events were ascertained from national hospitalisation and death registers; 
baseline cardiovascular disease (CVD) was ascertained from hospitalisation records and 
baseline health examination. Two outcome measures were used: any CHD (CHD death, non-
fatal MI or angina) and hard endpoint CHD (coronary death or non-fatal MI, excluding 
angina). Full details of the assessment of outcomes and covariates are provided in the Online 
Supplement.  
 
Statistical analyses 
We estimated the incidence of CHD outcomes per 1000 person years, and used Cox 
proportional hazards regression to model the associations between seropositivity and incident 
CHD. Full details of the statistical methods are provided in the Online Supplement. 
Multivariable-adjusted Cox models were adjusted for age (as the timescale  in the model), sex 
(binary), alcohol intake (grams of ethanol per week: 0, 1-49, 50-249, >=250), years of 
education (0–8, 9–12, >=12), BMI (kg/m2: < 18.5, 18.5-24.9, 25-29.9, 30-34.9, >=35), 
smoking (never, quit, pipe or cigars or 1-19 cigarettes per day, >=20 cigarettes per day), 
systolic and diastolic blood pressure (mmHg), total and HDL cholesterol, baseline diabetes 
and homoeostasis model assessment-estimated insulin resistance (HOMA-IR). Blood 
pressure, cholesterol and HOMA-IR were natural log-transformed for the analyses.  All 
analyses were conducted using Stata SE 14 (Stata Corporation, College Station, Texas, 
United States). 
 
Results 
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Our analyses were based on 6,887 men and women, of whom 562 were seropositive for Eu-
tTGA, 197 for Celikey-tTGA and 72 for EMA. In all, 937 participants had CVD at baseline. 
CVD was more common among seropositive than seronegative participants, but after 
adjustment for age, the odds of baseline CVD did not significantly differ between these 
groups (Table 1). 
 
During a median follow-up of 26 years (range: <1 to 32 years), 2,367 individuals experienced 
a CHD event. Age-adjusted Cox models provided no evidence for an association between 
antibody seropositivity and any CHD or hard endpoint CHD, and additional adjustment for 
pre-existing CVD or known CHD risk factors did not markedly alter the results (Table 2 and 
Online Supplement, Tables S1 and S1).  
 
To investigate whether tTGA positivity is related to CHD incidence independently of EMA, 
we post-hoc investigated CHD risk in participants who were positive for Eu-tTGA and 
Celikey-tTGA but negative for EMA (n=130). Again, multivariable-adjusted analyses 
provided no clear evidence for an association independently of age, sex, pre-existing CVD 
and other covariates (Table 2).  
 
Discussion 
Summary of main findings 
Our prospective investigation of over 6,800 Finnish men and women, who were followed up 
for up to three decades, provided no clear evidence for an association of tTGA or EMA 
seropositivity with incident CHD. Our findings support those of a previous register-based 
study conducted in Sweden, in which seropositivity was not associated with the risk of 
myocardial infarction or angina pectoris (HR: 1.14, 95% confidence interval, CI: 0.87, 1.50). 
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[23] In the latter investigation, however, the seropositive group included individuals who 
were positive for gliadin antibodies [23],  which can be detected not only in coeliac disease 
patients but also in healthy people as well as those with other autoimmune diseases [24-26]. It 
is thus possible that the seropositive group in this study represented a population 
heterogeneous in terms of the origins of their serological status. In the present study similar 
may be true of Eu-tTGA positive participants. In Mini-Finland Health Survey the 
seropositivity for Eu-tTGA (8.2%) was higher than the estimated prevalence of coeliac 
disease in the Finnish population overall (2.4%) [27]. This suggests that this group includes 
individuals with a mix of tTGA-associated conditions, such as ulcerative colitis or various 
forms of arthritis [28]. However, EMAs are pathognomonic for coeliac disease and the 
prevalence for seropositivity for the other two tests, Celikey-tTGA (2.9% of our study 
population) and EMA (1.0% of our participants) are closer to the estimated prevalence of 
coeliac disease, suggesting that the individuals positive for these tests are more likely to have 
elevated antibody levels related to gluten-induced autoimmunity. 
 
Taken together, our observations and the findings reported before suggest that seropositivity 
for tTGAs or EMAs is unlikely to explain the previously observed elevated CHD risk in 
individuals with coeliac disease. One possible explanation for the apparent discrepancy 
between laboratory-based investigations and human studies is that the angiogenesis-
regulating properties of tTGAs reported in cells and animal models [18-20]  do not translate 
to humans. It is also possible that the association is weak and that considerably larger studies 
than ours (with 235 incident CHD cases in the seropositive group) or Ludvigsson and 
colleagues’ (with 62 incident CHD cases) would be needed to ascertain sufficient power to 
detect it. However, the clinical significance of such a weak association is uncertain. Either 
way, although early diagnosis and initiation of gluten-free diet will undoubtedly improve the 
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prognosis and well-being of individuals with coeliac disease, they are unlikely to have a 
significant impact on CHD burden in this patient population. 
 
An important strength of our investigation is that we used prospectively collected data and 
register-based CHD outcomes, which are generally not prone to recall or other biases. Indeed, 
validation studies suggest that the Finnish hospitalisation and death registers have good 
coverage and reasonable diagnostic accuracy for CHD outcomes [29]. As Mini-Finland 
Health Survey had a 90% participation rate, with negligible amounts of missing data or 
attrition, it is unlikely that the latter have unduly biased our findings. Antibody measurements 
were missing from 3.1% of participants due to serum samples having been used up in other 
assays, and such data, likely to be missing completely at random, may have slightly biased 
our estimates towards the null. We examined the possibility of exposure misclassification in 
our data by testing a randomly selected sub-sample of 128 Eu-tTGA negative individuals for 
Celikey-tTG and EMA. No-one tested positive, suggesting that such exposure 
misclassification is unlikely. A further strength of our investigation is that we were able to 
adjust our estimates for a large number of covariates, which tend not to be available in studies 
based on electronic hospitalisation records only. We cannot, of course, exclude the possibility 
that our observations occurred due to chance. 
 
Implications for future research 
The mechanisms for the apparent association between coeliac disease and cardiovascular 
disease are not fully understood, but currently available evidence suggests several 
possibilities. Coeliac disease patients often suffer from chronic low level inflammation, 
which can drive atherosclerosis and vascular damage. [30]  A further possibility is that the 
malabsorption of nutrients, often observed in untreated disease or patients whose adherence 
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to gluten-free diet is poor, can lead to low circulating concentrations of folate or elevated 
concentrations of homocysteine, [31] which are implicated in the cardiovascular disease 
pathology. [32, 33] It is also possible that coeliac disease patients are more likely to receive 
diagnoses of other diseases and conditions due to their regular contact with healthcare 
professionals. These mechanisms would merit further research. 
 
Conclusion 
In a prospective study of over 6,800 Finnish men and women we found no clear evidence for 
an association of tTGA or EMA seropositivity with incident CHD outcomes, suggesting that 
tTG autoimmunity is unlikely to be the biological link between coeliac disease and CHD. 
Thus, although early diagnosis and initiation of gluten-free diet will undoubtedly improve the 
prognosis and well-being of individuals with coeliac disease, they are unlikely to have a 
significant impact on CHD burden in this patient population. 
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Table 1. Participant characteristics 
Baseline characteristic Eu-tTGA 
negative  
(n=6 325) 
Eu-tTGA 
positive 
(n=562) 
p vs. Eu-
tTGA 
negative 
Celikey tTGA 
positive (n=197) 
p vs. Eu-
tTGA 
negative 
EMA 
positive 
(n=72) 
p vs. Eu-
tTGA 
negative 
CVD (N, %) 812 (12.8) 125 (22.2) <0.0001 44 (22.3) <0.0001 6 (8.3) 0.3 
Female (N, %) 3 439 (54.4) 280 (49.8) 0.038 125 (63.5) 0.012 51 (70.8) 0.005 
Age (years) (mean, SD) 50.4 (13.9) 57.9 (14.2) <0.0001 59.6 (14.0) <0.0001 50.2 (11.4) 0.9 
Years of education (N, %) 
0-8 
9-12 
>=12 
 
4 241 (67.1) 
1 349 (21.3) 
735 (11.6) 
 
427 (76.0) 
98 (17.4) 
37 (6.6) 
 
<0.0001 
 
151 (76.7) 
33 (16.8) 
13 (6.6) 
 
0.013 
 
45 (62.5) 
19 (26.4) 
8 (11.1) 
 
0.6 
Alcohol intake (N, %) 
None 
1-49 gr ethanol/week 
50-249 gr ethanol/week 
250+ gr ethanol/week 
 
2 826 (44.7) 
2 749 (43.5) 
257 (4.10 
493 (7.8) 
 
292 (52.0) 
215 (38.3) 
16 (2.9) 
39 (6.9) 
 
0.008 
 
119 (60.4) 
61 (31.0) 
5 (2.5) 
12 (6.1) 
 
<0.0001 
 
40 (55.6) 
30 (41.7) 
1 (1.4) 
1 (1.4) 
 
0.07 
BMI (kg/m2) (N, %) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
>=35 
 
308 (4.9) 
2 611 (41.3) 
2 461 (38.9) 
779 (12.3) 
166 (2.6) 
 
31 (5.5) 
206 (36.7) 
236 (42.0) 
73 (13.0) 
16 (2.9) 
 
0.3 
 
15 (7.6) 
65 (33.0) 
87 (44.2) 
24 (12.2) 
6 (3.1) 
 
0.1 
 
6 (8.3) 
30 (41.7) 
30 (41.7) 
4 (5.6) 
2 (2.8) 
 
0.3 
Smoking (N, %) 
Never smoked 
Ex-smoker 
Pipe/cigars/1-19 cigarettes/day 
20+ cigarettes/day 
 
3 499 (55.3) 
1 302 (20.6) 
952 (15.1) 
572 (9.0) 
 
333 (59.3) 
123 (21.9) 
68 (12.1) 
38 (6.8) 
 
0.048 
 
134 (68.0) 
35 (17.8) 
18 (9.1) 
10 (5.1) 
 
0.003 
 
51 (70.8) 
8 (11.1) 
8 (11.1) 
5 (6.9) 
 
0.06 
Diabetes (N, %) 329 (5.2) 52 (9.3) <0.0001 28 (14.2) <0.0001 2 (2.8) 0.4 
Systolic blood pressure (mmHg) (mean, SD) 145.5 (23.6) 152.1 (26.0) <0.0001 153.8 (26.7) <0.0001 143.9 (25.7) 0.6 
Diastolic blood pressure (mmHg) (mean, 
SD) 
87.1 (11.7) 88.4 (13.1) 0.0109 87.1 (12.8) 0.9 85.4 (10.9) 0.2 
Total cholesterol (mmol/L)  (mean, SD) 6.9 (1.4) 6.9 (1.4) 0.6 6.6 (1.4) 0.0002 6.3 (1.2) 0.0002 
HDL cholesterol (mm/L) (mean, SD) 1.7 (0.4) 1.6 (0.4) <0.0001 1.6 (0.4) <0.0001 1.5 (0.3) 0.0008 
HOMA-IR3 (mean, SD) 2.5 (7.5) 2.8 (4.1) 0.4 3.6 (6.2) 0.0471 2.1 (1.5) 0.7 
1 CVD: cardiovascular disease. 
2 HDL: high-density lipoprotein cholesterol 
3
 HOMA-IR: homeostasis model assessment; insulin resistance  
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Table 2. Associations of antibody seropositivity with incident CHD 
Antibody test status Person-years 
at risk 
N CHD1 
(incidence per 
1000 person-
years) 
HR2 (95% CI) 
Adjusted for 
age 
HR2 (95% CI) 
Adjusted for age, 
sex and baseline 
CVD3 
HR2 (95% CI)  
Adjusted for age, sex, 
baseline CHD and 
covariates,3 
Eu-tTGA negative (n=6 325) 141 907 2 132 (15.0) 1 (ref.cat.) 1 (ref.cat.) 1 (ref.cat.) 
Eu-tTGA positive (n=562) 10 094 235 (23.3) 1.16 (1.05, 1.33) 1.06 (0.93, 1.22) 1.05 (0.92, 1.21) 
Celikey-tTGA positive (n=197) 3 470 80 (23.5) 1.04 (0.83, 1.30) 1.04 (0.82, 1.30) 1.04 (0.83, 1.30) 
EMA positive (n=72) 1 789 24 (13.4) 0.80 (0.54, 1.21) 1.00 (0.67, 1.51 1.16 (0.77, 1.74) 
      
Eu-tTGA and Celikey-tTGA 
positive, EMA negative (n=130) 
1 815 57 (31.4) 1.18 (0.90, 1.54) 1.06 (0.81, 1.38) 1.01 (0.77, 1.31) 
1 CHD: coronary heart disease 
2 HR: hazard ratio 
3 Covariates: level of education, BMI, smoking, alcohol intake, blood pressure, total cholesterol, HDL cholesterol, diabetes and HOMA-IR. 
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Associations of Tissue Transglutaminase Antibody Seropositivity with Coronary Heart 
Disease: Findings from a Prospective Cohort Study 
Katriina Heikkila, Harri Rissanen, Markku Heliövaara, Paul Knekt, Markku Mäki, Katri 
Kaukinen  
 
Clinical experience and observational studies suggest that individuals with coeliac disease are 
at increased risk of coronary heart disease (CHD), but the mechanism for this is unclear.  
 
Laboratory studies suggest that it may relate to tissue transglutaminase antibodies (tTGAs). 
 
In our prospective, population-based study of over 6,800 Finnish men and women, we fould 
no clear evidence for an association of seropositivity for tTGA and endomysial antibodies 
(EMAs) with incident CHD in humans. 
 
These findings suggest that though early diagnosis and initiation of gluten-free diet will 
undoubtedly improve the well-being of individuals with coeliac disease, they are unlikely to 
have a significant impact on CHD burden in this patient population. 
